💊 The @FDA pumps the breaks on the review process for drugmaker @EliLillyandCo candidate #Alzheimers #drug, #donanemab. buff.ly/49sKwft

🔬💉 #Lecanemab y #Donanemab, dos anticuerpos monoclonales, están en el foco de la ciencia por su capacidad para atacar la raíz del problema en el #Alzheimer : la acumulación de la proteína beta-amiloide. Detalles en la web de @RuberInter ruberinternacional.es/es/actualidad/…

In the wake of the FDA's decision to hold an Advisory Committee to learn more about #donanemab's unique trial design, our CSO, @a_hfillit, connected with @PharmaVoice on what this means for the #Alzheimers space & recent breakthroughs in #DrugDevelopment: bit.ly/43n2JJj

Potential #Alzheimer's drugs #donanemab and #lecanemab are undergoing further scrutiny as regulators take time to weigh up the benefits and risks, as reported by @guardian theguardian.com/society/2024/m…

Clinical benefits vs risks #Alzheimer’s "breakthrough" stalls: why a much-hyped anti-amyloid therapy is facing FDA approval delays - #scicomm via @guardian 🧠 #donanemab #aducanumab #lecanemab #ClinicalTrials #SideEffects theguardian.com/society/2024/m…

#Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays #donanemab #FDA #clinicaltrials theguardian.com/society/2024/m…

One of the many unique aspects of #donanemab's trial is that patients stopped receiving the drug once PET scans showed that the drug had cleared #amyloid. Our CSO, @a_hfillit, discusses the economic & clinical benefits of these stopping rules with @endpts: bit.ly/4a3Aqly

The #FDA decision to hold an Advisory Committee for #donanemab is likely due in part to the #AntiAmyloid drug's unique trial design. Our CSO, @a_hfillit, discusses the #biomarker-powered trial that used #tau staging and stopping rules in @biospace: bit.ly/4acT0HE

The @BCBSMA director involved in denying #lecanemab also said it’s “moot” because of the #donanemab results. Seemed surprised to hear it has higher ARIA rates and not better outcomes. I doubt has actually read any of these trials. Denying care without knowledge or transparency.

Slibný lék na #Alzheimera od Eli #Lilly s látkou #donanemab měl být schválený tento měsíc. #FDA ale ještě svolá panel nezávislých odborníků, kteří posoudí bezpečnost a účinnost nového léku. zdravezpravy.cz/2024/03/14/ame…

💊 While news about anti-amyloid drugs like #Leqembi and #donanemab stole the spotlight, #drug companies with other treatment approaches made major announcements and progressed in developing other kinds of drugs to treat #Alzheimers. 🔗 Here's more: buff.ly/4a8nHh2

The #FDA pushed back its target action date for #EliLilly's investigational #Alzheimers drug #donanemab. An advisory committee will discuss Lilly's TRAILBLAZER-ALZ 2 study, focusing on its "unique trial design" and potential impact on efficacy and safety. biospace.com/article/unique…

Better to be safe than sorry. Especially when it comes to #Alzheimers research. Especially when it comes to the lives of those living with this cruel disease. Especially when it comes to their hope *and their health. washingtonpost.com/business/2024/… #dementia #donanemab #caregivers

The @US_FDA has delayed the decision regarding the approval of #donanemab and will convene an advisory committee to discuss the results of the phase 3 #TRAILBLAZER-ALZ 2 clinical trial. #Alzheimer #AD @alzassociation practicalneurology.com/news/donanemab…

La @US_FDA retrasa la decisión sobre el uso de #donanemab para tratar la Enfermedad de #Alzheimer. Es la segunda vez que la FDA la demora. Eli Lilly cae, mientras que Biogen y Esai que comercializan fármacos rivales suben +1,8% y +4,7%, respectivamente tinyurl.com/4238nvxc

@axios: Setbacks reset views on highly touted Alzheimer's (#donanemab) and #ALS (#relyvrio) drugs. @SrPharmAssist buff.ly/3VjIWIq

Eli Lilly is seeking approval for its experimental #Alzheimer's drug #donanemab.It is an #antibody designed to clear #amyloid plaques in the brain linked to the disease. The #FDA was expected to make a decision on approving donanemab by this month, but has now delayed.

🧠 The @US_FDA pumps the breaks on the review process for drugmaker @EliLillyandCo's candidate #Alzheimers #drug, #donanemab. 📚 Read more here: beingpatient.com/donanemab-alzh…